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Abstract 18 
Effective methods to detect viable Mycobacterium tuberculosis (Mtb), the main causative agent 19 
of tuberculosis (TB) are urgently needed. To date, cultivation of Mtb is the gold standard which 20 
depends on initial sample processing with N-Acetyl-L-Cysteine/Sodium hydroxide (NALC/NaOH), 21 
chemicals that compromise Mtb viability and, consequently the performance of downstream 22 
tests. We applied culture and the novel Molecular bacterial load assay (MBLA) to measure the 23 
loss of Mtb viability following NALC/NaOH treatment of Mtb H37Rv pure culture and clinical 24 
sputa from pulmonary TB patients. Compared to untreated controls, NALC/NaOH treatment of 25 
Mtb, reduced MBLA detectable bacillary load (estimated colony forming units/milliliter 26 
(eCFU/mL) by 0.66±0.21log10- at 23
0C (P=0.018) and 0.72±0.08log10- at 30
0C (P=0.013). Likewise, 27 
NALC/NaOH treatment reduced viable count on solid culture by 0.84±0.02log10- at 23
0C 28 
(P<0.001) and 0.85±0.01log10- CFU/mL at 30
0C (P<0.001) respectively. The reduction in viable 29 
count was reflected by a corresponding increase in time to positivity of MGIT liquid culture, 1.2 30 
days at 230C (P<0.001), and 1.1 days at 300C (P<0.001). This NaOH-induced Mtb viability loss 31 
was replicated in clinical sputum samples, with bacterial load dropping by 0.65±0.17log10 from 32 
5.36±0.24log10- to 4.71±0.16log10- eCFU/mL for untreated and treated sputa respectively. 33 
Applying the Bowness et al model, revealed that the treated MGIT time to culture positivity of 34 
142hrs was equivalent to 4.86±0.28log10CFU, consistent with MBLA-measured bacterial load. Our 35 
study confirms the contribution of NALC/NaOH treatment to loss of viable bacterial count. Tests 36 
that obviate the need of decontamination may offer alternative option for accurate detection 37 
of viable Mtb and treatment response monitoring. 38 
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Introduction: 39 
Tuberculosis (TB) is one of the top 10 causes of death worldwide and the leading cause from a 40 
single infectious agent (1). In 2017, TB killed 1.7 million people of whom 0.3 million were co-41 
infected with HIV (1). One of the major challenges to control TB is the long duration of 42 
treatment, and the fact that appropriate diagnosis and monitoring the progress of treatment 43 
require rapid methods that quantify the number of viable Mycobacterium tuberculosis (Mtb)  in 44 
patient samples (2)   45 
Currently, diagnosis and treatment monitoring of TB rely on less sensitive sputum smear 46 
microscopy, and culture techniques that are compromised by contamination and slow to yield 47 
results (3). Despite the low sensitivity and inability to distinguish dead from viable Mtb, sputum 48 
smear microscopy remains the most commonly used test for diagnosis and monitoring (4, 5). In 49 
2011, the World Health Organization (WHO) rolled out a rapid, sensitive and specific DNA based 50 
Xpert MTB/RIF Assay (Cepheid, Sunnyvale, CA, USA) for diagnosis of TB. The Xpert MTB/RIF 51 
Assay has since then improved case detection rates of TB but not treatment outcomes (1, 5). 52 
DNA is a very stable molecule which take long period to degrade after cell death and thus 53 
cannot be used as a marker of viability and monitoring the bactericidal effect of anti-TB therapy 54 
(6). DNA positive test in treatment follow up specimens does not necessarily indicate viable 55 
bacilli and could be misleading assessment of treatment progress (4, 6–8). Unsuccessful 56 
attempts have been made to use the propidium monoazide, a dye which penetrates and 57 
inactivates DNA from dead cells so that test like Xpert/MTB RIF Assay can detect viable Mtb and 58 
be used for treatment monitoring (9, 10). 59 
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Cultivation of Mtb is the reference standard for TB diagnosis and treatment monitoring. Before 60 
culture, sputum samples must be decontaminated with chemicals to reduce growth of non-acid 61 
fast (AFB) bacteria and fungi that would otherwise outgrow the slow growing Mtb. N-Acetyl-L-62 
Cysteine combined with Sodium hydroxide (NALC/NaOH) usually performed for 15-20 minutes is 63 
the most recommended method (11, 12). NALC has a mucolytic property, it breaks di-sulfide 64 
bonds in sputum, exposing all bacteria to NaOH which kills fast-growing contaminants while 65 
maintaining Mtb viability. However, previous clinical studies have shown that, NALC/NaOH 66 
treatment reduces viable Mtb count on solid media and increase time to positivity (TTP) in 67 
liquid culture (13). Increasing the concentration of NaOH from 1% to 2% in order to eliminate all 68 
sputum contaminants resulted in higher rate of negative Mtb culture than the standard 69 
concentration of 1%, confirming the detrimental effect of NaOH on Mtb viability (11).  70 
Phenotypes of Mtb which do not grow in routine culture media without use of resuscitation 71 
promoting factors (rpfs) are increasingly being recognized (14, 15). One of the major 72 
characteristics of such bacterial phenotypes is that they are dominated with fatty cells which are 73 
rich in lipids, acid fast negative and difficult to eradicate with antibiotics (16, 17). It has been 74 
shown recently that NALC/NaOH decontamination combined with centrifugation step is 75 
associated with 90% loss of Mycobacterium smegmatis and that lipid poor cells (LP) are more 76 
susceptible to this effect than lipid rich (LR) cells (18). These emerging reports provide 77 
important evidence that detection of all sub-populations of Mtb in patient specimens may not 78 
be achieved using culture techniques or NALC/NaOH decontamination dependent tests.  79 
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Molecular bacterial load assay (MBLA) is a molecular test for detection of viable Mtb. It is a 80 
quantitative reverse transcriptase polymerase chain reaction (RT-qPCR) that quantifies Mtb load 81 
from patient sputum using the 16S ribosomal RNA (16S rRNA) as a reference gene. In contrast to 82 
culture, MBLA is rapid, sensitive, specific and does not require a NALC/NaOH decontamination 83 
step (7). Unlike mRNA which occurs in low copy number and exquisitely sensitive to 84 
degradation, the higher abundancy and relative stability of rRNA makes MBLA more sensitive 85 
and robust test. The MBLA test was acknowledged recently as a potential biomarker for TB 86 
treatment response monitoring replacing culture and smear microscopy and called for more 87 
studies to validate the test (1). 88 
 Previous studies using non-decontaminated sputa showed that MBLA has higher sensitivity 89 
than culture  (7, 19, 20). In this study we assessed whether like culture, the NALC/NaOH 90 
decontamination has effect on viable Mtb count measured by MBLA and if the effect is 91 
temperature dependent bearing in mind that temperature of laboratories in tropical areas may 92 
be high. 93 
Material and Methods 94 
Laboratory experiments were performed using five replicates of Mtb reference strain (H37Rv 95 
ATCC27294) and pooled sputum samples from pulmonary TB patients at NIMR-Mbeya Medical 96 
Research Centre (NIMR-MMRC), Tanzania. (Figure 1A and B) 97 
 98 
 99 
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H37Rv culture 100 
A single colony of Mtb (H37Rv ATCC 27294) from Lowenstein Jensen medium (LJ) was 101 
inoculated into Mycobacterial Growth Indicator tubes (BD BACTEC MGIT; Becton, Dickinson and 102 
Company MD, USA) supplemented with Oleic acid, Albumin, Dextrose and Catalase (OADC; 103 
Oxoid, United Kingdom). The culture was incubated in BACTEC MGIT 960 Culture System 104 
(Becton, Dickinson and Company, MD, USA). After fourteen days, the culture was mixed by 105 
vortexing, and 100L was sub-cultured into fresh MGIT cultures, incubated for another 106 
fourteen days and then used for the NALC/NaOH decontamination experiment and controls 107 
(Figure 1A) 108 
NALC/NaOH decontamination of H37Rv cultures 109 
The 2mL H37Rv culture at a concentration of ~107 CFU/mL were processed with equal volume 110 
of NALC/NaOH (1% final concentration of NaOH) at 23oC and 30oC for 20 minutes. For controls, 111 
another 2mL culture aliquots were treated with equal volume of phosphate buffer solution 112 
(PBS), pH 6.8 instead of NALC/NaOH (Figure 1A). Following exposure to NALC/NaOH at 230C and 113 
300C, cell pellets were harvested by centrifugation at 3000×g for 20 minutes at 40C. The pellets 114 
were serially diluted (10-fold dilutions) in PBS to determine the limit of detection (LoD) of each 115 
method. Each dilution was inoculated in MGIT culture and incubated for 42 days to determine 116 
the TTP. Quadruplicates of each dilution was inoculated on solid medium, Middlebrook 7H11 117 
(Becton, Dickinson and Company, MD, USA) using the Miles and Misra method (21) and 118 
incubated at 370C for colony count (Figure 1A). The 7H11 medium was supplemented with 119 
OADC (Oxoid, United Kingdom) and plates were observed weekly for any growth of Mtb 120 
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colonies up to 6 weeks. All culture media (7H11 and MGIT) for in vitro Mtb experiment were 121 
free from selective antibiotics.  122 
Patient sputum sample collection and processing 123 
We nested this study into the EIRMMA-TBT project (Evaluation of Implimentability of Rapid 124 
Molecular Monitoring Assay of Tuberculosis Treatment). Sputum samples collected for 125 
screening visit were tested for Mtb with Xpert MTB/RIF Assay. Five Mtb positive sputum 126 
samples were pooled and homogenized with a sterile magnetic stirrer for 30 minutes at room 127 
temperature. Thereafter, 1mL aliquots of pooled sputum (7 replicates) were sampled and 128 
processed for MBLA as controls. Second aliquots of 2mL (7 replicates) were decontaminated 129 
with NALC/NaOH prior to MBLA and liquid culture (Figure 1B). 130 
Confirmation of Mtb in liquid culture 131 
To confirm Mtb in culture, a rapid culture identification test (MPT64, Becton, Dickinson and 132 
Company, MD, USA) was performed following the manufacturer’s instructions. Blood agar (BA) 133 
were performed to exclude contaminations and for validation of TTP in MGIT culture. A drop of 134 
MGIT culture, ~20L was inoculated on BA and incubated for 48 hours at 370C. 135 
Molecular bacterial load assay (MBLA) 136 
RNA extraction 137 
Extraction of RNA was performed as previously described (20, 22). Briefly, 100L of extraction 138 
control (Vitalbacteria, SOI group, UK) was added to each tube prior to RNA extraction. The 139 
mixture was centrifuged at 3000×g for 30 minutes at room temperature and cell pellets were 140 
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suspended in 950uL of RNA pro blue solution (MP Biomedicals). Homogenization was 141 
performed for 40sec at 6000rpm using FAST prep instrument (MP Biomedicals) and RNA 142 
extracted using the FAST RNA pro kit (MP Biomedicals) following the manufacturer’s 143 
instructions. Removal of the genomic DNA was achieved by DNase treatment for 1hour at 37oC 144 
using the Ambion Turbo DNA free kit (Life Technologies). 145 
Reverse transcriptase polymerase chain reaction (RT-PCR) 146 
The RT-PCR was performed in the Rotor-Gene 5plex platform (Corbett research) using the 147 
Quantitect multiplex no ROX PCR mix (Qiagen, UK). Sequence specific primers and Taqman dual 148 
labelled probes for Mtb 16S rRNA and for extraction control (EC) target were procured from 149 
MWG Eurofins, Germany. Master mix preparation, PCR test conditions and amplification were 150 
set and performed as previously demonstrated (19, 20, 22). Sensitivity and specificity of primers 151 
and probes of MBLA were previously tested against non-tuberculosis mycobacteria including a 152 
wide range of respiratory pathogens and none of them was found to be amplified (19) 153 
Statistical methods 154 
Bacterial load estimated CFU/ml (eCFU/mL) by MBLA and actual CFU/mL count on solid media 155 
were normalized by log transformation. Then after, average, standard deviation (SD) and 156 
percentage positivity (%) for controls and NALC/NaOH treated cultures for each test were 157 
calculated using Microsoft excel (version 1810). Two-way analysis of variance (ANOVA) and 158 
then Sidak's multiple comparisons test were performed using GraphPad prism version 7.04 159 
(GraphPad Software, La Jolla, CA 92037 USA) to determine the difference in Mtb viability loss 160 
among NALC/NaOH treated cultures versus controls and different temperatures of treatment. 161 
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Independent t test was used to estimate the difference of Mtb bacterial load measured by 162 
MBLA between untreated and treated sputum. The MGIT-TTP from sputum culture were 163 
converted to CFU as previously published (23). Statistical significance was accepted at P<0.05. 164 
Ethical approval 165 
The EIRMMA-TBT study for which this analysis was nested, received approval from the Mbeya 166 
Medical Research Ethics Committee (MRH/R.10/18VOLL.VII/12), the National Health Research 167 
Ethics Committee (NatHREC) of the National Institute for Medical Research in Tanzania, 168 
(NIMR/HQ/R.8a/V01.IX) and the University of St Andrews Teaching and Research Ethics 169 
Committee (MD 12678) 170 
Results 171 
A total of five experimental repeats using five Mtb H37Rv cultures were performed between 172 
April 2017 to December 2018 (Figure 1A).  For clinical sputum samples, 22 mL of sputum was 173 
obtained after pooling five sputum samples from pulmonary TB patients. From the pooled 174 
sample, 21 one millilitre aliquots were made of which 7 untreated aliquots (controls) were 175 
MBLA tested (7x1mL each) and the remaining 14 were treated with NALC/NaOH (7x2mL each). 176 
Seven of the NALC/NaOH treated aliquots were tested by MBLA, MGIT liquid culture and 177 
indirect smear microscopy (Figure 1B). 178 
Bacterial load estimated by MBLA: The average bacterial load (±SD) of untreated culture was 179 
7.79±0.37log10- and 7.74±0.041log10- eCFU/mL at 23
0C and 300C respectively. In contrast the 180 
bacterial load of the NALC/NaOH treated cultures was 7.23±0.15log10- at 23
0C and 181 
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7.15±0.16log10- at 30
0C. Consequently, the NALC/NaOH treatment caused a viable bacterial 182 
load count reduction by 0.66±0.21log10- at 23
0C (P=0.0178) and 0.72±0.08log10- at 30
0C 183 
(P=0.0134) compared to controls in PBS (Figure 2A). This reduction was equivalent to 78.42% at 184 
230C and 80.34% at 300C respectively.  185 
Bacterial load by colony counts on solid media: Colony count of untreated culture (average ± 186 
SD) was 5.98±0.13log10- and 5.95±0.26log10- CFU/mL at 23
0C and 300C respectively. In contrast, 187 
colony count of the NALC/NaOH treated culture was 5.07±0.19log10- CFU/mL at 23
0C and 188 
5.04±0.23log10- CFU/mL at 30
0C. Compared to the untreated culture, NALC/NaOH treatment 189 
reduced colony count by 0.84±0.02log10- at 23
0C (P<0.001) and 0.85±0.01log10- CFU/ml at 30
0C 190 
(P<0.001) (Figure 2B). 191 
Time to positivity (TTP) in MGIT liquid culture: The median TTP (range) of untreated MGIT 192 
culture was 3.0 (2.2-3.4)- and 3.1 (2.1-3.3)- days compared to 4.2 (3.7-4.4)- and 4.2 (3.9-4.3)- 193 
days of the NALC/NaOH treated culture at 230C and 300C respectively. NALC/NaOH treatment 194 
increased TTP by 1.2 days (P<0.001) at 230C and 1.1 days (P<0.001) at 300C.The effect was 195 
independent of PBS and temperature of treatment (P>0.05) 196 
Assay positivity and limit of detection (LoD). The lowest bacterial load estimated by MBLA was 197 
84 eCFU/mL (20% positivity) and 840 eCFU/mL (100% positivity) at 230C, 8 eCFU/mL (20% 198 
positivity) and 84 eCFU/mL (20% positivity) at 300C respectively for untreated and treated 199 
cultures (Figure 3A). On solid culture, the LoD was 84 CFU/mL (20% positivity) for untreated 200 
controls and increased to 840 CFU/mL (60% positivity) at 230C and (40% positivity) at 300C after 201 
NALC/NaOH treatment (Figure 3B). The LoD of MGIT culture for untreated controls was 8 202 
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eCFU/mL (20% positivity) and 84 CFU/mL (20% positivity) at 23oC and 30oC respectively, which 203 
increased to ≥840 CFU/mL after NALC/NaOH treatment (Figure 3C).  204 
Bacterial load estimated by MBLA on sputum samples 205 
The average BL (±SD) of untreated fresh sputum was 5.36±0.24 log10- eCFU/mL and declined to 206 
4.71±0.16log10- eCFU/mL after NALC/NaOH decontamination. The decline was 0.65±0.17log10- 207 
eCFU/mL, equivalent to 78.74% loss of Mtb viability (Figure 4). 208 
Comparison of MGIT with MBLA for Mtb detection after NALC/NaOH treatment of sputum  209 
All the NALC/NaOH treated sputum aliquots yielded a positive MGIT culture result for Mtb, 210 
which was confirmed with MPT64 Ag test. True time to culture positivity (no contamination) 211 
was confirmed by negative result on blood agar. The average TTP of the 7 cultures was 212 
142±7.02hrs (5.97±0.29days). Using the Bowness et al TTP to CFU conversion model (23), we 213 
found the average TTP was equivalent to 4.86±0.28log10 CFU consistent with 4.71±0.16 log10 214 
eCFU/mL measured by MBLA same of treated sputum. The higher the TTP the lower the CFU, a 215 
relationship replicated by TTP and MBLA-measured bacterial load (Table 1). 216 
Discussion 217 
Rapid, sensitive and specific test with ability to discriminate viable from dead Mtb cells are 218 
crucial for accurate diagnosis and monitoring of TB treatment. To date, the contamination 219 
sensitive culture-based methods remain the reference standard for Mtb viability detection and 220 
treatment monitoring (1). The NALC/NaOH decontamination step performed before sputum 221 
culture has negative effect on viable Mtb and compromises the final culture results (24, 25). In 222 
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this study, we evaluated how NALC/NaOH decontamination process affects viable Mtb bacterial 223 
load count quantified by MBLA compared to culture methods in order to explore the benefits of 224 
this decontamination step free test. 225 
 Our findings concur with previous studies that have implicated NALC/NaOH treatment as cause 226 
of viable Mtb loss (11, 13). We show that this loss compromises the LoD of both culture and the 227 
MBLA. While previous studies used only culture to measure the NALC/NaOH-induced Mtb 228 
viability loss, our study has deployed the novel MBLA test to verify and confirm these findings. 229 
We demonstrate that NALC/NaOH treatment reduces viable Mtb by 0.66±0.21log10-eCFU/mL in 230 
pure cultures and 0.65±0.17log10- eCFU/mL in patient sputa. The reduction is consistently less 231 
than 1 log in both matrix types, which are understandably different in thickness, viscosity and 232 
sedimentation rate. Since 1% NaOH was used in both treatments, we hypothesise that the rate 233 
of loss is NaOH concentration dependent and independent of matrix type. Whereas this degree 234 
of loss is less likely to have negative impact on the test positivity of high TB burden patients, it 235 
may increase the likelihood of false negative test results for low burden patients.  236 
In addition, our result concur with the most recent in vitro work showing that NALC/NaOH 237 
decontamination is associated with 90% loss of M.smegmatis in culture (18). With MBLA test 238 
we observed Mtb viability loss of 78.42% and 80.34% in the in vitro Mtb experiments at 230C 239 
and 300C respectively, compared to 78.74% loss in real patient sputum samples at 230C. It is of 240 
note that, culture based estimates of Mtb viability may fail to detect viable but non-culturable 241 
bacteria (15).  242 
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The effect of non-culturable Mtb bacilli on culture positivity is more pronounced in solid than 243 
liquid culture (23, 26). Our study recapitulates this, showing that compared to solid culture, 244 
MBLA detected 2log10 -eCFU/mL more in the control samples and 1.5log10 -eCFU/mL more in 245 
the NALC/NaOH treated Mtb cultures (Figure 2A and B). Counts by solid culture are further 246 
complicated by the tendency of Mtb to clump which means each visible colony may not 247 
represent one cell, resulting in underestimation of the total viable bacteria count present in 248 
clinical samples (13). Therefore, decontamination step for solid culture increases the difficulty 249 
of interpreting result of viable counting by culture. By using MBLA, we were able to estimate 250 
the effect of NALC/NaOH-based decontamination on total viable Mtb count reflecting both 251 
culturable and non-culturable bacilli.  252 
Unlike solid culture, the LoD of MGIT culture was consistent to that of MBLA, detecting as low 253 
as 8- and 840- eCFU/mL in untreated and treated Mtb cultures respectively (Figure 3A and C). 254 
Likewise, all sputum aliquots were Mtb positive by MGIT and MBLA after NALC/NaOH 255 
treatment and was no difference on MBLA log10- eCFU/mL and log10 CFU of the converted MGIT-256 
TTP (Table 1). It is important to note that MGIT culture requires days or weeks to detect similar 257 
bacterial load that MBLA would detect and quantify within a matter of hours. Time to result for 258 
MBLA is independent of the amount of bacterial load and is not affected by contamination (7). 259 
However, in very low burden samples, it is possible for MGIT culture to yield a positive result as 260 
it depends on multiplication of Mtb cells over time rather than MBLA, which quantifies bacteria 261 
present in the sample at the time of RNA extraction.  262 
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Culture contamination rates are unacceptably high in tropical settings (27–30). We thus 263 
hypothesised that the high tropical temperatures in the range of 300C compromises activity of 264 
NALC/NaOH, leading to high growth of contaminants. However, we found no difference in Mtb 265 
viability loss for NALC/NaOH decontamination of Mtb cultures at 300C and 230C (Figure 2). This 266 
result suggests the same activity of NALC/NaOH at 230C and 300C and highlights the possibility 267 
that contamination of TB culture may not be related to the inefficiency of NALC/NaOH. It is 268 
possible that in absence of cold chain during transport of samples and storage, higher 269 
temperature environment may support growth of fast-growing contaminants to a 270 
concentration which may not be eliminated by NALC/NaOH (25, 31). 271 
We note that NALC/NaOH treatment is not the only cause of Mtb viable count loss. Processes 272 
such as homogenisation and centrifugation have been implicated as causes of viable count loss 273 
(18). By applying similar dilution, homogenisation and centrifugation processes to untreated 274 
and treated samples, we normalised any viable count loss that would occur due to these factors 275 
across the two arms. 276 
The limitation of our study is that experiments were performed using pure cultures and pooled 277 
clinical sputum samples with relatively high bacterial load. Therefore, we were not able to show 278 
the impact of NALC/NaOH-induced reduction of viable Mtb count in low burden samples. 279 
Pooled sputum sample from 5 patients is not large enough to represent the diversity of Mtb 280 
strains to confirm that indeed NALC/NaOH-induced loss of viable count in pure culture is the 281 
same as in clinical sputum samples. Furthermore, selective antibiotics which may reduce viable 282 
Mtb were not included in culture media for in vitro experiments but were included in MGIT 283 
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culture of clinical sputum aliquots. Addition of antibiotics may provide different results in 284 
culture (19). Nevertheless, our in vitro study design provided an opportunity to investigate the 285 
impact of NALC/NaOH on its own in absence of other stress like antibiotics and the use of pure 286 
culture was crucial to have untreated controls free of contaminants that would otherwise 287 
compromise our results (31).  288 
Future studies will explore the impact of NALC/NaOH treatment in a variety of sputum samples 289 
from patients with different levels of TB burden to verify impact on test results of low burden 290 
patients. We will also attempt to distinguish the viable count loss caused by chemical treatment 291 
from that stemming from centrifugation. Going forward, tests like MBLA which obviate the 292 
need for NALC/NaOH decontamination step could be potential alternative to culture detection 293 
of viable Mtb and for monitoring ant-tuberculosis treatment response.  294 
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  411 
FIGURE LEGENDS 412 
FIGURE 1. Flow diagram of laboratory experiments, conditions and downstream tests 413 
performed for Mtb cultures and sputum specimens. (A) In vitro Mtb experimental procedure 414 
employed for each decontaminated culture (B) Experimental flow of pooled patient sputum 415 
specimens. Note; 5 biological replicates of experiments were performed for in vitro Mtb cultures 416 
(1-5) and 7 replicates of sputum aliquots. 417 
FIGURE 2. NALC/NaOH decontamination reduces viable Mtb measured by MBLA and Solid 418 
media. (A) Mtb eCFU/mL reduction measured by MBLA and (B) CFU/mL reduction on 419 
Middlebrook (7H11) at 23
0
C and 30
0
C respectively. Error bars represent mean value with 420 
22 
 
standard error of the mean (SEM) (N=5 independent biological replicates on different Mtb 421 
cultures).  422 
FIGURE 3. NALC/NaOH decontamination compromise test positivity and detection limit. (A) 423 
Effect on MBLA positivity, (B) positivity of solid media (Middlebrook 7H11) and (C) positivity of 424 
MGIT liquid culture. (N=5 independent biological replicates on different Mtb cultures). 425 
FIGURE 4: NALC/NaOH decontamination of sputum reduces viable Mtb measured by MBLA. 426 
Independent t-test, P<0.0001 between fresh sputum and treated pellet. Each dot represents 427 
value of each sputum aliquot (N=7 aliquots) 428 
Table 1: MGIT-CFU matches with MBLA after NALC/NaOH decontamination. MBLA of 429 
untreated sputum is a reference control to indicate the effect on NALC/NaOH treatment. 430 
Independent t test (P=0.24), between MGIT-CFU and MBLA of treated pellet and (P<0.01), 431 
between MGIT-CFU with MBLA of untreated sputum. (N= 7 replicates of sputum aliquots tested. 432 
SD; standard deviation) 433 
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 471 
 472 
Figure 4 473 
 474 
  MBLA of untreated 
sputum 
MBLA of the treated 
pellet 
MGIT culture of the treated 
pellet 
Sputum aliquot Log10 (eCFU/mL) Log10 eCFU/mL TTP (hours)  Log 10 CFU (after 
TTP conversion) 
1 5.47 4.96 135 5.14 
2 5.55 4.67 145 4.74 
3 5.28 4.71 138 5.02 
4 5.51 4.83 145 4.74 
5 5.60 4.72 149 4.58 
6 4.94 4.44 132 5.26 
7 5.15 4.62 150 4.54 
AVERAGE 5.36 4.71 142 4.86 
SD 0.24 0.16 7.02 0.28 
Table 1 475 
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